Kindred Biosciences (KIN) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Kindred Biosciences Announces First Quarter 2015 Financial Results
May 8, 2015 9:02 AM EDTSAN FRANCISCO, May 8, 2015 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the first quarter ended March 31, 2015 and provided updates on its programs. Â
Development Updates
KindredBio continues to advance a diversified portfolio of validated molecules in a capital efficient manner and has over 20 programs in development. Some of the highlights include:
The pivotal field trial of SentiKind, a KCNQ potassium channel agonist for post-operative pain in dogs, continues to enroll well and the Company expects to report topline results on this... More
